Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence—a retrospective cohort study

医学 四分位间距 甲状腺癌 内科学 回顾性队列研究 淋巴结 阶段(地层学) 肿瘤科 免疫组织化学 癌症 甲状腺乳突癌 比例危险模型 病理 甲状腺癌 胃肠病学 甲状腺 古生物学 生物
作者
Meili Zhang,Jialei Gu,Wendong Wang,Kejing Wang,Ling Zheng,Feng Jiang,Jinbiao Shang
出处
期刊:Gland surgery [AME Publishing Company]
卷期号:11 (12): 1908-1923 被引量:4
标识
DOI:10.21037/gs-22-701
摘要

Identifying the high recurrence group of patients with early-stage papillary thyroid cancer (PTC) is the greatest challenge in the management of this disease. It has been noted that B-type Rafkinase (BRAF) V600E mutation and programmed death ligand 1 (PD-L1) are associated in PTC and highly expressed in PTC, correlating in PTC as potential prognostic biomarkers. However, whether they can be used to predict the aggressiveness and recurrence of early PTC remains unclear.Clinicopathological data of 137 patients with early PTC [tumor-node-metastasis (TNM) stage I-II] who underwent surgery in Zhejiang Cancer Hospital between 2008 and 2010 were retrospectively analyzed. BRAFV600E mutation and PD-L1 was detected by immunohistochemistry. The median follow-up time was 136 months (interquartile range 5.8). The presence of tumor confirmed by imaging or pathology or lymph node metastasis was considered as tumor recurrence. The association of both alone and in combination with clinicopathological features and recurrence was statistically analyzed respectively. The risk of recurrence was assessed using Cox regression models.Most of the 137 early PTC were female (78.1%). The mean age was 43.2±12.1 years. The median tumor size was 1.4 cm; 14 patients developed recurrence during follow-up period; 56 patients (40.9%) were detected positive for BRAFV600E mutation; 76 patients (55.5%) were detected positive for PD-L1. Patients with both BRAFV600E mutation and PD-L1 expression had larger tumors (P=0.038), were more likely to have extrathyroidal invasion (P=0.045), and had a lower rate of cervical lymph node metastasis (P=0.046). The recurrence rate was 17.5% (7/40) in patients with BRAFV600E mutation and PD-L1 double expression compared to 8.9% (4/45) in patients with BRAFV600E mutation and PD-L1 double negative [hazard ratio (HR) =1.267; 95% CI: 0.841-1.909; P=0.257]. Survival curves showed flatter recurrence-free survival (RFS) curves in positive BRAFV600E mutation only and PD-L1 expression only, whereas decreased sharply in positive expression of both BRAFV600E mutation and PD-L1; however, the differences were not significant (P>0.05).The combination of BRAFV600E mutation and PD-L1 to identify group at higher risk of recurrence in early PTC has insufficient clinical evidence and should be used with caution in the clinical management of PTC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我家电脑完成签到 ,获得积分10
刚刚
Akim的应助被雀巢早生蚝采纳,获得10
1秒前
星星完成签到,获得积分10
1秒前
hsy309完成签到,获得积分10
1秒前
景景景发布了新的文献求助10
2秒前
眼睛大的傲菡完成签到,获得积分10
3秒前
anyon完成签到,获得积分10
3秒前
3秒前
li完成签到,获得积分10
4秒前
4秒前
木子发布了新的文献求助10
5秒前
钟嘉霖完成签到,获得积分10
5秒前
小小发布了新的文献求助100
6秒前
Maestro_S的应助被Kenny采纳,获得10
6秒前
天际小山完成签到,获得积分10
8秒前
8秒前
xing发布了新的文献求助10
8秒前
9秒前
丁鹏笑完成签到 ,获得积分0
9秒前
孟昊如完成签到,获得积分10
9秒前
null的应助被aaa采纳,获得10
10秒前
11秒前
13秒前
英姑的应助被aoa采纳,获得10
14秒前
15秒前
15秒前
清汐完成签到 ,获得积分10
15秒前
那当然完成签到 ,获得积分10
16秒前
16秒前
苗浩阳完成签到,获得积分10
18秒前
Shirley发布了新的文献求助10
19秒前
ChaseY完成签到 ,获得积分10
20秒前
xing发布了新的文献求助10
20秒前
科目三的应助被sinmon采纳,获得10
21秒前
WK完成签到,获得积分10
21秒前
22秒前
执着的青烟完成签到,获得积分10
22秒前
22秒前
22秒前
ice完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160961
求助须知:如何正确求助?哪些是违规求助? 9555819
关于积分的说明 21730291
捐赠科研通 7750940
什么是DOI,文献DOI怎么找? 3427477
关于科研通互助平台的介绍 2552515
邀请新用户注册赠送积分活动 2471912